

Mary E Law

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5566193/publications.pdf>

Version: 2024-02-01

13
papers

388
citations

1307594

7
h-index

1125743

13
g-index

14
all docs

14
docs citations

14
times ranked

771
citing authors

#	ARTICLE	IF	CITATIONS
1	Inhibitors of ERp44, PDIA1, and AGR2 induce disulfide-mediated oligomerization of Death Receptors 4 and 5 and cancer cell death. <i>Cancer Letters</i> , 2022, 534, 215604.	7.2	4
2	Anticancer Agents Derived from Cyclic Thiosulfonates: Structure-Activity Relationships. <i>ChemMedChem</i> , 2022, 17, .	3.2	1
3	Repurposing Tranexamic Acid as an Anticancer Agent. <i>Frontiers in Pharmacology</i> , 2021, 12, 792600.	3.5	4
4	Disulfide bond-disrupting agents activate the tumor necrosis family-related apoptosis-inducing ligand/death receptor 5 pathway. <i>Cell Death Discovery</i> , 2019, 5, 153.	4.7	9
5	A novel proteotoxic combination therapy for EGFR+ and HER2+ cancers. <i>Oncogene</i> , 2019, 38, 4264-4282.	5.9	8
6	Loss of sirtuin 1 and mitofusin 2 contributes to enhanced ischemia/reperfusion injury in aged livers. <i>Aging Cell</i> , 2018, 17, e12761.	6.7	60
7	The unfolded protein response as a target for anticancer therapeutics. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 127, 66-79.	4.4	102
8	Disulfide bond disrupting agents activate the unfolded protein response in EGFR- and HER2-positive breast tumor cells. <i>Oncotarget</i> , 2017, 8, 28971-28989.	1.8	11
9	CUB domain-containing protein 1 and the epidermal growth factor receptor cooperate to induce cell detachment. <i>Breast Cancer Research</i> , 2016, 18, 80.	5.0	25
10	Cyclin-Dependent Kinase Inhibitors as Anticancer Therapeutics. <i>Molecular Pharmacology</i> , 2015, 88, 846-852.	2.3	79
11	Signaling Mechanisms that Suppress the Cytostatic Actions of Rapamycin. <i>PLoS ONE</i> , 2014, 9, e99927.	2.5	3
12	Identification of a small molecule inhibitor of serine 276 phosphorylation of the p65 subunit of NF- κ B using in silico molecular docking. <i>Cancer Letters</i> , 2010, 291, 217-224.	7.2	18
13	Rapamycin Disrupts Cyclin/Cyclin-Dependent Kinase/p21/Proliferating Cell Nuclear Antigen Complexes and Cyclin D1 Reverses Rapamycin Action by Stabilizing These Complexes. <i>Cancer Research</i> , 2006, 66, 1070-1080.	0.9	63